Autologous Unselected Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease (AutoChron)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03000296|
Recruitment Status : Active, not recruiting
First Posted : December 22, 2016
Last Update Posted : January 15, 2021
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Crohn's Disease Inflammatory Bowel Diseases Gastroenteritis||Procedure: Autologous Hematopoietic Stem Cell Transplantation||Not Applicable|
Crohn's disease (CD) is a chronic, refractory inflammatory bowel disease that affects the entire digestive tract associated with intestinal and extra intestinal manifestations or other autoimmune diseases. Conventional therapy for Crohn's disease includes anti-inflammatory, immunosuppressant and/or biologic drugs/corticosteroids. This treatment benefits the majority of patients. However, a proportion of patients fail to achieve complete and long-term disease control and often require multiple intestinal surgeries with a risk of developing short bowel syndrome.
Hematopoietic stem cell transplantation (HSCT) has been proposed to cause lymphoablation and reset of the immune system as an alternative strategy to induce long-term disease control in this high-risk population.
This study enrolled Crohn's disease patients not responsive to conventional therapy.
Initially safety and the clinical outcome will be evaluated. The selected patients will be admitted to the bone marrow transplant (BMT) unit for the mobilization regimen using cyclophosphamide (Cy - 60 mg/kg) and G-CSF (10 mcg/kg/day) from the 5th day after Cy administration until harvesting progenitor cells from peripheral blood by leukapheresis.
After seven days of rest, the conditioning regimen consists of Cy (200 mg/kg total dose for four days), rabbit antithymocyte globulin (6.5 mg/kg total dose for four days) and methylprednisolone (500 mg/day).
The clinical course of patients with refractory Crohn´s disease will be evaluated to determine the efficacy of HSCT as a therapeutic tool including the adverse aspects of the procedure, clinical outcome and quality of life.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Autologous Unselected Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease|
|Study Start Date :||October 2013|
|Actual Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||December 2024|
Experimental: Hematopoietic Stem Cell Transplantation
High doses immunosuppression Cyclophosphamide (200 mg/kg total dose for four days) and rabbit antithymocyte globulin (6.5 mg/kg total dose for four days) followed by unselected autologous hematopoietic stem cell transplantation rescue.
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Hematopoietic stem cell transplantation Lymphoablation followed by hematopoietic stem cell transplantation to rescue the immune system.
- Safety of unselected autologous HSCT in refractory Crohn´s disease patients [ Time Frame: 12 months ]HHSCT safety will be analyzed by laboratory tests and treatment-related adverse events. Safety will be evaluated by treatment-related adverse events. All adverse events will be recorded in a standardized way and their relationship to the study protocol will be assessed at different short- and long-term time points.
- Crohn´s Disease Activity Index (CDAI) [ Time Frame: 12 months ]Duration of disease remission, defined as a CDAI ≤ 150, will be assessed at 1, 3, 6, 12 and 24 months after transplant.
- CRAIG Crohn´s Severity Score (CSS) [ Time Frame: 12 months ]The CRAIG CSS will be assessed at 1, 3, 6, 12 and 24 months after transplant.
- Inflammatory Bowel Disease Questionnaire (IBDQ) [ Time Frame: 24 months ]The IBDQ will be administered at 1, 3, 6, 12 and 24 months after transplant.
- Short Form-36 Health Survey (SF-36) [ Time Frame: 24 months ]The SF-36 will be administered at 1, 3, 6, 12 and 24 months after transplant.
- Simple Endoscopic Activity Score (SES) [ Time Frame: 24 months ]The SES will be assessed at 6, 12 and 24 months after HSCT.
- Crohn's Disease Endoscopic Index of Severity (CDEIS) [ Time Frame: 24 months ]The CDEIS will be assessed at 6, 12 and 24 months after HSCT.
- Rutgeerts endoscopic score [ Time Frame: 24 months ]Rutgeerts endoscopic score will be assessed at 6, 12 and 24 months after HSCT.
- Harvey & Bradshaw Index (HBI) [ Time Frame: 24 months ]The HBI will be assessed at 1, 3, 6, 12 and 24 months after HSCT.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||14 Years to 70 Years (Child, Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Age between 14 and 50 years (patients aged 50 - 70 can participate at the principal investigators discretion).
Confirmed diagnosis of active Crohn's disease:
- Diagnosis of Crohn's disease based on typical radiological findingsand or typical histology at least 6 months prior to screening.
Active disease at the time of registration to the trial, defined as
*Crohn's Disease Activity Index (CDAI) > 150, and ii) Two of the following:
- Harvey Bradshaw Index > 4
- Endoscopic evidence of active disease confirmed by histology
- Clear evidence of active small bowel Crohn's disease on computed tomography (CT) or magnetic resonance (MR) enterography.
- Unsatisfactory course despite immunosuppressive agents (usually azathioprine, methotrexate and two biologic agents (normally infliximab, adalimumab and/or certolizumab) in addition to corticosteroids. Patients should have relapsing and refractory disease despite thiopurines, methotrexate and/or infliximab/adalimumab/certolizumab maintenance therapy or clear demonstration of intolerance / toxicity to these drugs.
- Current problems unsuitable for surgery or patient at risk for developing short bowel syndrome.
- Prepared to undergo additional study procedures as per trial schedule
- Patient has undergone intensive counseling about risks
- Pregnancy or unwillingness to use adequate contraception during the study, in women of childbearing age. Unwillingness of using appropriate contraceptive measures in males.
Concomitant severe disease
- renal: creatinine clearance < 30 mL/min (measured or estimated)
- cardiac: clinical evidence of refractory congestive heart failure; left ventricular ejection fraction < 40% by multigated radionuclide angiography (MUGA) or cardiac echo; chronic atrial fibrillation necessitating oral anticoagulation; uncontrolled ventricular arrhythmia; pericardial effusion with hemodynamic consequences as evaluated by an experienced echo cardiographer.
- pulmonary: diffusion capacity <40%
- psychiatric disorders including active drug or alcohol abuse
- concurrent or recent history of malignant disease (excluding non-melanoma skin cancer)
- uncontrolled hypertension, defined as resting systolic blood pressure ≥ 140 and/or resting diastolic pressure ≥ 90 despite at least 2 anti-hypertensive agents.
- uncontrolled acute or chronic infection with HIV, Human T-lymphotropic virus (HTLV-1 or 2), hepatitis viruses or any other infection the investigators consider a contraindication to participation.
- other chronic disease causing significant organ failure.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03000296
|Sao Jose do Rio Preto, SP, Brazil, 15015-750|
|Principal Investigator:||Milton A Ruiz, MD, PhD||Beneficencia Portuguesa|
|Responsible Party:||Milton Artur Ruiz, MD,PhD., Beneficência Portuguesa de São Paulo|
|Other Study ID Numbers:||
|First Posted:||December 22, 2016 Key Record Dates|
|Last Update Posted:||January 15, 2021|
|Last Verified:||January 2021|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
|Plan Description:||The main objective is to observe the safety and clinical benefit of autologous HSCT therapy in refractory patients with Crohn's disease. Evaluation during transplant period and 1, 3, 6, 12 and 24 months post-transplant. Safety be evaluated by the amount of treatment-related adverse events. Record adverse events in a standardized way. Secondary outcome measures will be disease remission: 1, 3, 6, 12 and 24 months post-transplant both clinical and endoscopic remission. The percentage of patients in sustained disease remission at 1, 3, 6, 12 and 24 months post HSCT will be determined. Sustained disease remission is defined as a CDAI < 150; HBI <4, CCSI< 16, without the use of corticosteroids, immunosuppressant or biologic agents. Mucosal healing will be assessed during ileocolonoscopy at 6, 12, and 24 months following HSCT using SES, CDEIS and Rutgeerts endoscopy index. Heath Quality life, Short Form 36 and IBDQ at 1 3 6 12 and 24 months post-Transplant.|
hematopoetic stem cell transplant
Bone marrow transplant
Inflammatory Bowel Diseases
Digestive System Diseases